All lobbying filings

AVENUE SOLUTIONS

Lobbying for MERCK & CO. INC. · developer, manufacturer and distributor of pharmaceuticals

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · District of Columbia · House · Senate · $50,000.00 income · posted Jul 21, 2025

Official filing document

Bills named in this filing 5

HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
HCONRES 14
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appro…
HR 946
ORPHAN Cures Act
S 1862
ORPHAN Cures Act
HR 4299
Protecting Patient Access to Cancer and Complex Therapies Act

Lobbying activity 2

Health Issues

Health care issues in H.R.1, To provide for reconciliation pursuant to title II of H. Con. Res. 14 (Public Law No: 119-21); Issues related to vaccines

Medicare/Medicaid

Value of prescription drugs; Issues related to Medicare Parts B and D; Issues related to Medicare and Medicaid coverage and reimbursement; H.R. 946/S. 1862, ORPHAN Cures Act; Issues related to cyclic peptides; Issues related to Average Sales Price (ASP) and Part B Medicare negotiation; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R.4299, Protecting Patient Access to Cancer and Complex Therapies Act

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.